O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
M Hermisson, A Klumpp, W Wick… - Journal of …, 2006 - Wiley Online Library
Temozolomide (TMZ) is a methylating agent which prolongs survival when administered
during and after radiotherapy in the first‐line treatment of glioblastoma and which also has …
during and after radiotherapy in the first‐line treatment of glioblastoma and which also has …
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
M Hermisson, A Klumpp, W Wick… - Journal of …, 2006 - europepmc.org
Temozolomide (TMZ) is a methylating agent which prolongs survival when administered
during and after radiotherapy in the first-line treatment of glioblastoma and which also has …
during and after radiotherapy in the first-line treatment of glioblastoma and which also has …
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
M Hermisson, A Klumpp, W Wick… - Journal of …, 2006 - pubmed.ncbi.nlm.nih.gov
Temozolomide (TMZ) is a methylating agent which prolongs survival when administered
during and after radiotherapy in the first-line treatment of glioblastoma and which also has …
during and after radiotherapy in the first-line treatment of glioblastoma and which also has …
[PDF][PDF] O 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
M Hermisson, A Klumpp, W Wick… - Journal of …, 2005 - academia.edu
Temozolomide (TMZ) is a methylating agent which prolongs survival when administered
during and after radiotherapy in the first-line treatment of glioblastoma and which also has …
during and after radiotherapy in the first-line treatment of glioblastoma and which also has …
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
M Hermisson, A Klumpp, W Wick… - Journal of …, 2006 - search.ebscohost.com
Temozolomide (TMZ) is a methylating agent which prolongs survival when administered
during and after radiotherapy in the first-line treatment of glioblastoma and which also has …
during and after radiotherapy in the first-line treatment of glioblastoma and which also has …
[引用][C] O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
M HERMISSON, A KLUMPP, W WICK… - Journal of …, 2006 - pascal-francis.inist.fr
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity
in human malignant glioma cells CNRS Inist Pascal-Francis CNRS Pascal and Francis …
in human malignant glioma cells CNRS Inist Pascal-Francis CNRS Pascal and Francis …
[引用][C] O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
M Hermisson, A Klumpp, W Wick… - Journal of …, 2006 - cir.nii.ac.jp
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity
in human malignant glioma cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
in human malignant glioma cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
[引用][C] O^ 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
M HERMISSON - J Neurochem, 2006 - cir.nii.ac.jp
O^6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity
in human malignant glioma cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
in human malignant glioma cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …